DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
12/06/2018 - 8:00 pm | Corporate | Finance
Monthly information regarding the total number of voting rights and total number of shares of the CompanyDownload PDF (88 KB)
11/20/2018 - 7:30 am
DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic ChildrenDownload PDF (415 KB)
11/16/2018 - 7:30 am
DBV Technologies Appoints Daniel Tassé as Chief Executive OfficerDownload PDF (451 KB)